GAMMA Investing LLC Buys 28,921 Shares of Twist Bioscience Co. (NASDAQ:TWST)

GAMMA Investing LLC increased its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 6,499.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 29,366 shares of the company's stock after buying an additional 28,921 shares during the period. GAMMA Investing LLC's holdings in Twist Bioscience were worth $1,153,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of TWST. First Light Asset Management LLC acquired a new stake in shares of Twist Bioscience in the fourth quarter valued at approximately $56,984,000. Marshall Wace LLP grew its holdings in Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock worth $39,319,000 after buying an additional 840,828 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after buying an additional 532,040 shares in the last quarter. American Century Companies Inc. increased its position in Twist Bioscience by 63.5% in the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock valued at $35,148,000 after acquiring an additional 293,751 shares during the period. Finally, ARK Investment Management LLC raised its stake in Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after acquiring an additional 237,772 shares in the last quarter.

Twist Bioscience Stock Up 4.5%

NASDAQ:TWST traded up $1.52 on Monday, hitting $35.04. 922,616 shares of the company's stock traded hands, compared to its average volume of 976,192. The company has a market cap of $2.10 billion, a PE ratio of -10.37 and a beta of 2.38. Twist Bioscience Co. has a 1 year low of $27.12 and a 1 year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm has a 50-day moving average price of $34.05 and a 200-day moving average price of $41.52.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Equities analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,726 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the transaction, the chief executive officer now owns 660,966 shares in the company, valued at approximately $27,549,062.88. The trade was a 0.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Adam Laponis sold 936 shares of the firm's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $27,846.00. Following the completion of the transaction, the chief financial officer now directly owns 106,018 shares of the company's stock, valued at approximately $3,154,035.50. This trade represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,920 shares of company stock worth $814,067 in the last 90 days. 3.01% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of research reports. Robert W. Baird decreased their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group decreased their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Guggenheim reissued a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. Finally, Barclays reduced their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.